Corrigendum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.
Corrigendum: Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.
复制标题
勘误表：VSV-埃博拉疫苗接种后的人类抗体库识别出新靶标和病毒中和 IgM 抗体。
DOI：
10.1038/nm0217-264c
复制
发表时间：
2017
期刊：
影响因子：
82.9
通讯作者：
Beigel,JohnH
中科院分区：
文献类型：
--
作者：
Khurana,Surender;Fuentes,Sandra;Coyle,ElizabethM;Ravichandran,Supriya;DaveyJr,RichardT;Beigel,JohnH
在这篇文章最初在线发表的版本中，作者省略了承认资助机构和研究人员提供假病毒体中和试验数据。声明部分已经修改为：“我们感谢美国陆军传染病医学研究所的团队，包括S。奎拉斯湾Wisniewski和J. Hooper提供了本研究中使用的假病毒体中和试验数据。假病毒体的研究是由美国国防部医学对抗系统联合疫苗采购项目资助的，该项目位于马里兰州的德特里克堡。本文所载的意见，解释，结论和建议是作者的意见，不一定得到美国国防部的认可。此错误已在本文的所有版本中更正。
In the version of this article initially published online, the authors omitted acknowledging a funding agency and researchers for providing the pseudovirion neutralization assay data. The acknowledgments section has been revised to state,“We thank the US Army Medical Research Institute of Infectious Diseases team, including S. Kwilas, M. Wisniewski and J. Hooper, for providing the pseudovirion neutralization assay data used in this study. The pseudovirion work was funded by the US Department of Defense (DoD) Medical Countermeasures Systems’ Joint Vaccine Acquisition Program at Fort Detrick, Maryland. The opinions, interpretations, conclusions and recommendations contained herein are those of the authors and are not necessarily endorsed by the US DoD.” The error has been corrected for all versions of this article.